Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail

Mithun Sharma1, Madhumita Premkumar2, Anand V Kulkarni*1, Pramod Kumar1, D Nageshwar Reddy3 and Nagaraja Padaki Rao1

1Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India; 2Department of Hepatology, PGI MER, Chandigarh, India; 3Department of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a global epidemic that is likely to become the most common cause of chronic liver disease in the next decade, worldwide. Though numerous drugs have been evaluated in clinical trials, most of them have returned inconclusive results and shown poorly-tolerated adverse effects. None of the drugs have been approved by the Food and Drug Administration for treating biopsy-proven non-alcoholic steatohepatitis (NASH). Vitamin E and pioglitazone have been extensively used in treatment of biopsy-proven non-diabetic NASH patients. Although some amelioration of inflammation has been seen, these drugs did not improve the fibrosis component of NASH. Therefore, dietary modification and weight reduction have remained the cornerstone of treatment of NASH; moreover, they have shown to improve histological activity as well as fibrosis. The search for an ideal drug or ‘Holy Grail’ within this landscape of possible agents continues, as weight reduction is achieved only in less than 10% of patients. In this current review, we summarize the drugs for NASH which are under investigation, and we provide a critical analysis of their up-to-date results and outcomes.

Citation of this article: Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for non-alcoholic steatohepatitis (NASH): Quest for the holy grail. J Clin Transl Hepatol 2021;9(1):40–50. doi: 10.14218/JCTH.2020.00055.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is an emerging global epidemic. It is the most common cause of chronic liver disease in the western world.1 The pooled prevalence of NAFLD in Asia is 30% (95% confidence interval [CI]: 28.13–31.15).2 The term nonalcoholic steatohepatitis (NASH) was coined almost 4 decades ago.3 Recently, NAFLD was renamed as “metabolic (dysfunction)-associated fatty liver disease”, or “MAFLD”.4 However, the change in terminology is unlikely to alter the management of these patients and hence will not be referred to in this manuscript. In this review, instead, we will focus on the drugs used for NASH.

Abbreviations: CI, confidence interval; FDA, Food and Drug Administration; FXR, farnesoid X receptor; NASH, non-alcoholic fatty liver disease; NAFLD, nonalcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; OCA, obeticholic acid; PIVENS, pioglitazone versus vitamin E; TONIC, ursodeoxycholic acid; UDCA, ursodeoxycholic acid.

Keywords: Fatty liver; NAFLD; NASH; Obeticholic acid; Saroglitazar.

For the approval of a drug for a disease, it needs to undergo preclinical trials, followed by Phase 1 safety studies, which are supported by Phase 2 studies. Phase 2 studies are dose-finding trials and aid in evaluating efficacy of a drug. Once a drug is found to be effective, it undergoes Phase 3 studies that compare the safety and efficacy of the drug with existing therapies. Then, the drug is placed for review before an appropriate drug review committee that may/may not approve the drug.12 Post-approval, there are phase 4 trials, a strategy which is also known collectively as ‘post-marketing surveillance’. The objective of the phase IV studies is to check the drug’s performance in real-life scenarios, to study the long-term risks and benefits of the drug, and to discover any rare side effects. Interestingly, for each phase of the trial, there are recommended endpoints to be achieved before proceeding to the next stage of a trial in adult patients, such as those with NASH.13 However, there are no clear endpoints for pediatric NASH.13 For NASH, the endpoint for a phase 3 trial is NASH resolution (defined as disappearance of ballooning and disappearance or persistence of minimal, lobular inflammation that does not qualify for the diagnosis of NASH), with or without a reduction in fibrosis stage by one point.13

There are certain major hindrances to conducting a clinically relevant trial in NASH.14,15 Some of the limiting factors are:
1. Biopsies are required to define participants and are needed to establish efficacy, as well.
2. Many trials have high screen fail rate, due to stricter inclusion criteria.
3. There is often a high placebo response rate in the control group. The reasons for this are unclear but may be due to behavioral changes in the control group, resulting in weight loss.

Copyright: © 2021 Authors. This article has been published under the terms of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided: "This article has been published in Journal of Clinical and Translational Hepatology at DOI: 10.14218/JCTH.2020.00055 and can also be viewed on the Journal's website at http://www.jcht.net.com".

Review Article
4. Most of the studies use two primary endpoints.
   4a. Improvement in fibrosis, with no worsening of NASH
   4b. NASH resolution without worsening of fibrosis

5. Challenges in developing clinical endpoints, due to the lack of specific symptoms of NASH.

6. Difficulties in managing confounders, such as recording alcohol intake before and during the study, and the lack of uniformity in diet and physical activity.

Histopathology and grading of NASH

There are two major grading systems of NASH. One which is frequently used in clinical trials is NAFLD Activity Score—Clinical Research Network (NAS-CRN) and has been validated to compare the biopsies. NAS-CRN consists of three components of activity, viz. steatosis (score 0–3), lobular inflammation (score 0–3), and ballooning (score 0–2), with a maximum score of 8. A score ≥5 suggests definite NASH. Fibrosis is graded from 0–4 (0: no fibrosis to 4: cirrhosis). NAS-CRN has been validated in both children and the adult population. The Steatosis activity fibrosis (SAF) scoring system aids in the diagnosis of NASH and can be used in clinical trials. The SAF score is semi-quantitative and differs slightly from the NAS-CRN, with lobular inflammation scored from 0 to 2 (instead of 3) and ballooning from 0–2 (1: clusters, reticulated cytoplasm; 2: enlarged hepatocytes, as opposed to few and many in NAS-CRN scoring). As the final score is meant to represent a diagnosis, steatosis must be >0, wherein activity (ballooning plus lobular inflammation) must be ≥2, in which ballooning is at least 1. Fibrosis is based on the NASH-CRN scale and is reported as “F”.

Pathogenesis and targets

To find an ideal drug for NASH, it is essential to understand its pathogenesis and identify a single ideal target. The target may exist at multiple levels and may also be outside the liver itself. Whether NAFLD is the ‘hepatic manifestation’ of metabolic syndrome or a pathogenic determinant of metabolic syndrome is still unknown. However, there is a growing body of evidence strongly supporting the notion that NAFLD precedes the development of type 2 diabetes mellitus (T2DM) and metabolic syndrome. It is also a paradox to find out if the drugs that is appropriate for lean and obese NASH patients would be similar. An ideal drug for NASH would be a drug that targets fat deposition, has anti-inflammatory and antifibrotic properties, and reduces cardiovascular risk, which is the most frequent cause of mortality in NASH. The pathogenesis of NAFLD is complex, involving extrinsic predisposing factors and intrinsic genetic factors. Insulin resistance, however, remains central to the development of NAFLD. The complex interplay of different factors in pathogenesis is shown in Fig. 1.

Currently, drug treatment is indicated for patients with progressive NASH (i.e. NASH activity with bridging fibrosis/cirrhosis), early-stage NASH (at high risk for disease progression; age >50 years, metabolic syndrome, diabetes mellitus or increased alanine transaminase), or NASH with high necroinflammatory activity. Most of the pharmacotherapy trials have been carried out in biopsy-proven NASH patients (biopsy is must to prove NASH/inflammation). Several drugs have shown initial promise but failed to meet the critical endpoint of improvement in fibrosis scores. The drugs and modalities of treatment that have been tried in patients with NASH are discussed below.

Lifestyle changes for the treatment of NASH

The most effective and proven therapy for NASH is weight loss. Analysis of data from eight randomized control trials has shown that >5% weight loss leads to resolution hepatic steatosis, and ≥7% improves the inflammatory score of NAS (NAFLD activity score). But, reportedly, only 50% of patients can achieve a weight loss of 7%. Lastly, a weight loss of ≥10% results in the resolution of early fibrosis, in approximately 45% of subjects. Physical activity of ≥150 m/week is associated with improvement in liver enzymes, irrespective of the weight loss. More than 8,000 steps per day is associated with a reduction in all-cause mortality; however, the number of steps required for reduction in NAS score/liver enzymes has not been evaluated.

Dietary interventions

A triple hit behavioral phenotype exists, which involves 1)
sedentary behavior, ii) low physical activity, and iii) poor diet, all of which are well known to be associated with poor cardio-metabolic health, NAFLD, and overall mortality. Along with physical activity, a healthy diet is recommended for NAFLD patients. Refined sugar and sugar-sweetened beverages are a common source of empty calories. These fructose-rich diets increase the hepatic synthesis of triglycerides. Hence, sugar-sweetened beverages should be avoided. Mediterranean diet is primarily plant-based (whole grains, legumes, fruit, vegetables), low in carbohydrates (limited simple sugars and refined carbohydrates), and rich in monounsaturated (mostly olive oil) and omega-3 fats, and which incorporates limited red meat, ad low-fat dairy products, which has been shown to improve the hepatic steatosis and insulin resistance and is the recommended diet for NAFLD patients. However, there was no improvement in fibrosis. There have been conflicting reports on the rise in all-cause mortality in patients receiving vitamin E. However, a small increase in prostate cancer due to long term administration of vitamin E is known. Though the drug is well tolerated, the current guidelines recommend vitamin E (rrr-α-tocopherol) at a daily dose of 800 IU/day in non-diabetic adults with biopsy-proven NASH, weighing the risk-benefit ratio before initiation of treatment. Currently, the time-tested diet and exercise therapy remains the most effective and cost saving intervention for management of NAFLD.

**Drugs**

**Antioxidants**

**Vitamin E:** Vitamin E has been studied in the landmark PIVENS (adult patients) and TONIC trials (pediatric population), where the antioxidative and free radical scavenging property of vitamin E has been hypothesized to improve NASH. Indeed, there was a significant improvement in steatosis and inflammation in patients treated with vitamin E for 96 weeks compared to placebo. However, there was no improvement in fibrosis. There have been conflicting reports on the rise in all-cause mortality in patients receiving vitamin E. There is conflict in the results of the PIVENS study. Pioglitazone has been hypothesized to increase the adipocyte uptake of fatty acids, thereby potentially drawing fat away from the hepatocytes. vitamin E has been hypothesized to improve NASH. In the same PIVENS study, Pioglitazone has been hypothesized to increase the adipocyte uptake of fatty acids, thereby potentially drawing fat away from the hepatocytes. The use of 30 mg of pioglitazone for 96 weeks in non-diabetic patients showed a significant improvement in NASH compared to placebo. However, there was no improvement in fibrosis. The major drawback of vitamin E and pioglitazone is that they do not show a significant improvement in NASH compared to placebo. However, there was no improvement in fibrosis. The use of 30 mg of pioglitazone for 96 weeks in non-diabetic patients showed a significant improvement in NASH compared to placebo. However, there was no improvement in fibrosis.

**Pioglitazone:** Pioglitazone, an agonist of peroxisome proliferator-activated receptor (PPAR) γ, was evaluated in the same PIVENS study. Pioglitazone has been hypothesized to increase the adipocyte uptake of fatty acids, thereby potentially drawing fat away from the hepatocytes. The use of 30 mg of pioglitazone for 96 weeks in non-diabetic patients showed a significant improvement in NASH compared to placebo. However, there was no improvement in fibrosis. The major drawback of vitamin E and pioglitazone is that they do not show a significant improvement in NASH compared to placebo.

**Ursodeoxycholic acid (UDCA):** UDCA at a dose of 13–15 mg/kg body weight in patients with biopsy-proven NASH has not shown any benefit when compared with placebo and is not recommended for NASH. Animal studies on a side-chain-shortened homologue of UDCA, nor- (n)UDCA, can attenuate the progression of NASH. A recent human study (phase 2 trial) reported significant improvement in serum ALT levels at 12 weeks with the use of nUDCA at 1,500 mg per day compared to placebo. Further phase III studies are required to confirm if the drug can meet the recommended endpoints.

**Omega-3 fatty acids:** Omega-3 fatty acids can reduce oxidative stress, lipotoxicity, and inflammation in patients with NASH. There have been conflicting reports about efficacy of omega-3 fatty acids in NAFLD. The optimum dose has not yet been determined. However, the benefits of omega-3 fatty acid supplementation have been noted with a dose of ≥0.83 g/day. Currently, they can be used to treat hypertriglyceridemia in NASH but not for the treatment of NAFLD or NASH.

**Metformin:** Early studies with metformin showed improvement of insulin resistance, liver chemistries, and a modest reduction in hepatic steatosis. Subsequently, two meta-analyses with the use of metformin in NASH showed no benefit and are currently not recommended for the treatment of NASH.

**Pentoxifylline (PTX):** PTX inhibits several pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α. PTX increases hepatic gluconeogenesis and inhibition of formaldehyde in mice with steatohepatitis induced by a methionine choline-deficient diet and reduces the production of oxygen radicals induced by prolonged ischemia time in rat livers. PTX down-regulates profibrogenic cytokines and procollagen I expression in a rat model of biliary duct obstruction. Although preclinical studies have demonstrated the efficacy of PTX in NASH, there are conflicting reports in human trials of PTX. PTX is currently not recommended for NASH, due to insufficient evidence.

**Drugs in the pipeline for NASH**

The increasing burden of NASH worldwide has kept researchers astute to discover a new drug. NASH is associated with a high lifetime economic burden. In the absence of treatment, the total direct cost of illness for these patients will continue to grow. Several drugs are in the pipeline for the treatment of NASH. Although none of these drugs appear as ideal, many of them seem promising. Some of these drugs are detailed in Table 1.

**Obeticholic acid (OCA):** Bile acid receptor agonists are abundant in the liver, kidney, adipose tissue, small intestine, and immune cells. OCA, 6α-ethyl chenodeoxycholic acid (INT 747), is a semi-synthetic derivative of chenodeoxycholic acid. It is a 100-times more potent agonist of FXR than chenodeoxycholic acid. OCA is rapidly absorbed orally and reaches a peak plasma concentration in approximately 1.5 hours after intake and has a steady-state half-life of 4 days. The drug is not affected by food intake. The mean volume distribution of OCA is 618 L and is about 99% protein bound. The liver extensively metabolizes it into glycine and taurine conjugates. OCA undergoes extensive enterohepatic circulation, and >85% of metabolites are excreted in feces. FXR activation is mediated by binding of OCA to FXR receptors, which leads to increased secretion of FGF19 from the ileum. This results in formation of the β-klotho-FGF4-FGF19 complex, which inhibits CYP7A1 expression and bile acid synthesis. Besides, there is an increase in bile salt exporter protein (known as BSEP) and multidrug resistance 3 (known as MDR3) protein, promoting efflux of bile from hepatocytes. Further, OCA has a mild suppressive effect on the transforming growth factor-beta gene and extracellular matrix reorganization and stellate cell activation. The mechanism of action of OCA is summarized in Fig. 2.

The phase 2b study of OCA in NASH, called the ‘FLINT’
study, showed a significant improvement of NAS score by ≥2 points, without worsening of fibrosis, in 45% of patients receiving OCA at 25 mg, as compared with 21% in placebo (p=0.0002). Thirty-five percent in the OCA group also showed improvement in fibrosis compared to 19% in the placebo group (p=0.004). However, this study was terminated early due to administrative reasons. This was followed by a subsequent phase 3 study (the REGENERATE trial) involving 2,400 NASH patients with F2-3 fibrosis. They were randomized in 1:1:1 ratio to receive either placebo or OCA at 10 mg or OCA at 25 mg per day for 48 weeks. An interim analysis at 18 months on 931 patients showed improvement in fibrosis by ≥1 stage, with no worsening of fibrosis compared to 19% in the placebo (p=0.0002). Thirty-five percent in the OCA group, as compared with 21% in patients receiving OCA at 25 mg, when compared with 12% in the placebo arm (p=0.0002) and 18% in the OCA 10 mg group (p=0.04 for placebo). A dose-dependent decrease in liver chemistry was observed from 3 months to 18 months. Similarly, improvement in NAS score by 2 points without worsening of fibrosis was significantly higher in the OCA 25 mg group when compared to placebo (36% vs. 24%; p=0.0012), with no such difference between the OCA 10 mg and placebo groups (30% vs. 24%; p=0.11). Considering the vast number of NASH patients worldwide, this promising data would help to avoid many of the liver transplants attributable to NASH. Recent studies have shown that underlying genetic abnormalities may identify a cohort of patients who would respond to OCA.

Pruritus and a rise in low-density lipoprotein cholesterol (LDL) are the two major concerns with the use of OCA. The most common side effect reported with OCA is pruritus. Pruritus on treatment was reported in 19% of patients on placebo compared to 28% with OCA at 10 mg and 51% with OCA at 25 mg. Nearly 10% had to discontinue OCA (25 mg) due to pruritus compared to 1% each in the OCA 10 mg and placebo arms. The general concern for a physician is identifying pruritus in an asymptomatic disease. However, in a recent abstract, the interim analysis of the REGENERATE trial showed lower patient-reported outcomes than the general population on a specific questionnaire (the chronic liver disease questionnaire-NASH), and the patient-reported outcomes improved with OCA treatment. The authors further argued that pruritus is present in 21% of individuals at baseline, which is also unclear. Female gender, gastrointestinal comorbidity, and psychiatric comorbidity were associated with clinically important low itch score. However, data suggested that OCA-related pruritus occurs early in the treatment, without any subsequent worsening or negative impact on patient-reported outcomes. Importantly, thus far, OCA is the only drug to have met the endpoint of fibrosis improvement.

Besides, OCA therapy increases small very low-density lipoprotein (VLDL) particles, large and small LDL particles, and reduces high-density lipoprotein particles at 12 weeks, which reverses after drug discontinuation. Whether this leads to an increased risk of cardiovascular mortality in NASH patients is not yet known. Concurrent use of statins (in the CONTROL trial) lowered the LDL cholesterol to below baseline as early as 4 weeks after initiation and has an acceptable tolerability profile. The FDA approved OCA in 2016 for use in primary biliary cholangitis at a dose of 5–10 mg/day for non-responders in Child A cirrhosis and non-cirrhotics. While the recommended dose for Child B/C cirrhosis is 5 mg/weekly, to a maximum dose of 10 mg twice weekly.

**PPAR agonists**

These are a group of nuclear receptor proteins that act as modulators of gene expression by functioning as transcription factors. They have a role in lipid, protein and carbohydrate metabolism, as well as in cellular differentiation. Fibrates consist of fenofibrate, clofibrate, gemfibrozil, are PPARα agonists. They help in breakdown and transport of fatty acid and are found in abundance in the liver, skeletal muscle, and endothelial cells. Studies with fibrates in NASH did not show any difference in the improvement in either steatosis or fibrosis. A possible reason for their ineffectiveness in humans is because of the lower expression of PPARα in humans when compared to mouse models. Thiazolidinediones (TZD), pioglitazone, and rosiglitazone are PPARγ agonists. PPARγ, which is mainly located in the ad-
6 (Pioglitazone has been discussed in insulin sensitivity.64 They have shown to improve glucose uptake and increase fatty acid oxidation, and insulin secretion, leading to improvement in insulin sensitivity.64,65 Pioglitazone, a weak PPARγ agonist, showed a significant decrease in serum ALT and total hepatic lipid content and an increase in adiponectin expression in mouse models.65 In a trial of 55 patients with impaired glucose tolerance (or T2DM), pioglitazone administered with a hypocaloric diet improved steatosis and inflammation but not fibrosis.66 Even in the PIVENS trial, there was no improvement in fibrosis.6 (Pioglitazone has been discussed in the previous paragraph). Rosiglitazone, a potent PPARγ agonist, on the other hand, has shown some beneficial effects in rodent models.67 Rosiglitazone improved steatosis and transaminase levels, despite significant weight gain.64 Even prolonged therapy of rosiglitazone had no substantial improvement in NAS score.68 A meta-analysis of four trials did not show improvement in fibrosis with the use of TZD therapy; although, there was a significant improvement in steatosis and inflammation.69 Weight gain remains the major concern associated with the use of TZD.6,64,70

PPARβ/δ agonists, are universally present in all cells of the body and are involved in regulating mitochondrial metabolism and fatty acid beta-oxidation.71 The data regarding the effectiveness of PPAR agonists for the treatment of NAFLD are limited, precluding formulation of any conclusions.72

**Dual agonists:** Glitazars are a group of drugs that have PPARα/γ agonism and can improve dyslipidemia and insulin resistance.73 Muraglitazar and aleglitazar posed severe safety concerns for cardiovascular events and weight gain and were withdrawn.74,75 Saroglitazar, a dual PPARα/γ agonist, was recently approved by the Drugs Controller General of India (known as the DCGI) for the treatment of NASH. Saroglitazar has promising results in the treatment of NASH. Elafibranor, a PPARα/δ agonist, also had favorable results in preclinical trials. Bezafibrate is also a dual PPARα/δ agonist and has some in vitro studies supporting its use in NASH, but there are no clinical studies on its efficacy in NASH.76

**Saroglitazar:** PPARα agonism is thought to affect fatty acid catabolism/dyslipidemia, while PPARγ has an impact on glycemic control and insulin sensitization. A combination of fenofibrate (PPARα) and rosiglitazone (PPARγ) improved diabetic dyslipidemia and glycemic control.77 Saroglitazar is a dominant PPARα agonist and is effective in improving insulin sensitivity.78,79 Saroglitazar in mice has shown to ameliorate NASH through down-regulation of the hepatic lipopolysaccharide/toll-like receptor-4 pathway and inhibition of adipocyte dysfunction.80 Saroglitazar prevents weight gain, normalizes liver enzymes, improves insulin resistance, dyslipidemia, and hepatic inflammation in NASH mice.80 Saroglitazar also led to a significant change in adipokine levels, resulting in a substantial decrease in serum leptin and TNF-α level.80 In NASH models, saroglitazar reduced hepatic steatosis, inflammation, ballooning, and fibrosis.81 It also reduced liver enzymes and the expression of inflammatory and fibrosis biomarkers. Saroglitazar led to a significant reduction in the NAS score, better than that achieved with pioglitazone and fenofibrate.81,82 The mechanism of action of saroglitazar is shown in Fig. 3. A recent randomized multicenter placebo-controlled trial using different doses of saroglitazar (the EVIDENCE IV trial) was presented as an abstract at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). Saroglitazar at 4 mg improved dyslipidemia, hepatic steatosis, and insulin resistance, when compared to placebo (L010 AASLD 2019).83 Another phase 3 multicenter, double-blind, randomized study concluded that saroglitazar at 4 mg for 52 weeks improved NAS score, transaminitis, and lipid profile without fibrosis worsening [Abstract 1427, APASL liver meet 2020 Hepatol Int (2020) 14 (Suppl 1): S326].

**Elafibranor:** Elafibranor (GFT505) is a PPARα/δ agonist under evaluation for the treatment of NASH. It has been shown in in vivo studies on Western diet-fed, human apolipoprotein E2 transgenic mice to improve steatosis, inflammation, and fibrosis.84 The study also demonstrated that the drug decreased hepatic lipid accumulation and inhibited pro-inflammatory and profibrotic gene expression. In the initial multicenter, double-blind placebo-controlled randomized tri-

![Proposed mechanism of action of OCA in NASH](Image 90x508 to 515x732)
al (the GOLDEN-505 trial), elafibranor at 80 mg and 120 mg were compared against placebo for treatment of NASH for 52 weeks. In the intention-to-treat (ITT) analysis, no difference was noted in the protocol-defined primary outcome, which was NASH resolution without fibrosis worsening. However, in a post ad hoc modified endpoint, NASH resolution without fibrosis worsening was higher with elafibranor at 120 mg compared to placebo (19% vs. 12%; p=0.045). Improvement in NAS score was seen in 20% of patients with elafibranor at 120 mg compared to only 11% in the placebo group (p=0.018). Elafibranor was associated with a mild reversible rise in serum creatinine but had no adverse effects on cardiac profile or body weight. Recently, the disappointing results of the phase 3 trial on elafibranor (the RESOLVE-IT trial) were announced. In the ITT analysis of 1,070 patients, the response rate (NASH resolution without fibrosis worsening) was 19.2% for patients who received elafibranor at 120 mg compared to 14.7% for the placebo arm. Twenty-five percent of patients who received elafibranor at 120 mg achieved fibrosis improvement compared to 22.4% in the placebo arm. There was also no significant improvement in other biochemical parameters.

Lanifibranor (IVA337) is a pan-PPAR agonist, which has been shown to improve all the histological factors of NASH, including fibrosis, in experimental mouse models. A phase 2 randomized placebo-controlled trial is under evaluation for assessing the safety and efficacy of lanifibranor in patients with T2DM and NAFLD (NCT03459079).

Arachidyl-amido cholanoic acid (aramchol): Aramchol is an inhibitor of stearoyl-CoA desaturase 1 (known as SCD1), which is an enzyme located in the endoplasmic reticulum and catalyzes the rate-limiting step of monounsaturated fatty acid formation and prevents de novo lipogenesis. Initial studies on the methionine and choline-deficient diet model of NASH showed down-regulation of SCD1, along with increasing flux through the trans-sulphuration pathway, thereby maintaining cellular redox homeostasis.

A double-blind, multicenter placebo-controlled trial on biopsy-proven NASH comparing aramchol at 100 mg or 300 mg against placebo for 3 months concluded that there was significant reduction in hepatic fat content with aramchol at 300 mg. An open-labeled safety study was conducted on 16 healthy volunteers (Abstract #2326 Liver meeting AASLD 2019). Twice-daily dosing with aramchol at 300 mg resulted in significantly higher exposures than once-daily dosing of aramchol at 600 mg. Both dosing regimens were safe and tolerable, without any adverse effects. Currently, a double-blind, placebo-controlled randomized phase 3 study with aramchol at 300 mg in subjects with NASH and F2-3 who are overweight (or obese) and have prediabetes or adequately controlled T2DM (the ARMOR study) is underway (NCT04104321).

Cenicriviroc (CVC): CVC is a dual human C-C motif chemokine receptor type 2 and 5 (CCR2/CCR5 chemokine) antagonist. CVC-mediated antagonism of CCR2 reduces the recruitment, migration, and infiltration of pro-inflammatory monocytes and macrophages at the site of liver injury. CCR5 antagonism by CVC is expected to additionally impair the migration, activation, and proliferation of collagen-producing activated hepatic stellate cells/myofibroblasts.

The CENTAUR phase 2b study included patients with NAS score ≥4 and NASH-CRN fibrosis stage 1–3. The study concluded that CVC improved fibrosis in patients with NASH, and most of these improvements occur at year 1 and are maintained until the end of the 2nd year. Phase 3 (the AURORA study) trial is designed to strengthen the findings of this drug further. In this multicenter, randomized, double-blind, placebo-controlled study (NCT030328740) of approximately 2,000 adults with histological evidence of NASH and F2-3 fibrosis will be randomized in 2:1 ratio to oral CVC 150 mg or placebo once daily. The primary efficacy endpoint includes the proportion of subjects with ≥1-stage improvement in liver fibrosis and no worsening of steatohepatitis at 1 year. The results are expected by September 2020.

Glucagon-like peptide-1 (GLP-1) inhibitors: Liraglutide is a human incretin (GLP-1) agonist. Liraglutide allevi-
lated the features of metabolic syndrome in rats fed with a high-fat diet.99 Liraglutide improved glucose tolerance, reduced weight gain, triglyceride levels, and liver fat accumulation.98 The initial randomized controlled trial comparing liraglutide at 1.8 mg against placebo for 12 weeks. Liraglutide reduced the body mass index, improved hepatic and adipose tissue insulin sensitivity, and also improved glycemic control, all of which form the major component in NASH pathogenesis.97 A subsequent multicenter randomized phase 2 placebo-controlled trial (the LEAN trial) found that liraglutide is safe, well-tolerated, and leads to histological resolution of NASH (39% vs. 9% in placebo; \( p=0.019 \)).99 The progression of fibrosis was also more significant in the placebo arm (36% vs. 9%; \( p=0.04 \)). Common side effects with liraglutide were gastrointestinal in 81% of patients, and the most common were nausea and diarrhea.98 There are conflicting reports of increased incidence of pancreatic cancer and acute pancreatitis with this incretin analogue.99,100 However, further studies are ongoing comparing liraglutide and bariatric surgery in obese Asian NASH patients, and results are awaited (NCT02654665).

Semaglutide is another GLP-1 agonist discovered in 2012 and approved for the treatment of T2DM since 2017. It is currently being investigated for NASH. A double-blind placebo-controlled trial for 52 weeks with semaglutide and lifestyle modification has shown significant weight loss compared to liraglutide and placebo.101 The cardiovascular outcomes of 104 subjects with dose of semaglutide at 0.5 or 1.0 mg/week in T2DM (the SUSTAIN-6 trial; NCT01720446) and a 52-week weight management trial with a dose of semaglutide at 0.05-0.4 mg/day (NCT02453711) were analyzed. Semaglutide had cardioprotective effects in T2DM patients. Among subjects treated with semaglutide (especially at 0.4 mg/day), the proportion of patients with metabolic syndrome approximately halved during the trial compared with the baseline.102 Semaglutide also reduced inflammatory markers and aminotransferases.103 The investigation of semaglutide at 0.1, 0.2 and 0.4 mg/day for NASH resolution without fibrosis worsening after 72 weeks of therapy has recently been completed, and the results are expected (NCT02970942).

**Galectin-3 inhibitors (GT-MD-02):** Galectins are conserved proteins with the ability to bind β-galactosides through carbohydrate-recognition domains.103 Galectin-3 contains a C-terminal carbohydrate-recognition domain linked to an N-terminal protein-binding domain and is a unique chimeric galectin.103 In the cytoplasm, galectin-3 is vital for cell survival due to its interaction with specific survival-associated proteins. In the nucleus, galectin-3 promotes pre-mRNA splicing and regulates gene transcription, whereas extracellular galectin-3 modulates cell-cell interactions. Thus, it is involved in cell differentiation, inflammation, fibrogenesis, and the host defense.104 Galectoarabinino-rhamnogalacturonan, belapentin (GR-MD-02), binds mostly to galectin-3 receptors and has been hypothesized to manipulate the upstream events in the pathogenesis of NASH, which leads to substrate overload.105 The sequential dose-ranging, placebo-controlled, double-blinded safety study in biopsy-proven NASH patients with advanced fibrosis (Brunn stage 3) revealed no difference in adverse effects when GR-MD-02 single or three weekly repeated doses of 2, 4 or 8 mg/kg was used.106 Galectin-3 ablation protects from diet-induced NASH by decreasing hepatic advanced lipoxidation end products’ accumulation, with attenuation of inflammation, hepatocyte injury, and fibrosis.106 A multicenter placebo-controlled trial has enrolled patients with NASH, cirrhosis, and portal hypertension to randomly receive biweekly infusions of belapentin at a dose of 2 mg/kg or 8 mg/kg or placebo for 52 weeks. Although belapentin was safe, it was not associated with a significant reduction in hepatic venous pressure gradient (HVPG) or fibrosis compared to placebo. In the subgroup analysis of patients without esophageal varices, 2 mg/kg belapentin did reduce HVPG and development of varices.108

**Emricasan:** Emricasan is a pan-caspase inhibitor that acts on the final apoptotic pathway involved in the pathogenesis of NASH. In a murine model of NASH, hepatocyte apoptosis was attenuated by emricasan, which led to an improvement in fibrosis, bringing forth the use of emricasan as an antifibrotic agent in NASH.109 A subsequent multicenter study involving cirrhotic patients (etiology: alcohol, hepatitis C virus, and NASH) demonstrated a significant reduction in model for end-stage liver disease (MELD score), Child-Pugh scores, international normalized ratio, and total bilirubin in patients with MELD scores ≥15 following emricasan 25 mg.110 A multicenter, double-blind, randomized trial recruited 263 patients with NASH-related cirrhosis and baseline HVPG of ≥12 mmHg. These patients were treated with twice-daily with oral emricasan at 5 mg, 25 mg or 50 mg, or placebo in a 1:1:1:1 ratio for up to 48 weeks. The primary endpoint was change in HVPG (ΔHVPG) at week 24. Secondary endpoints were changes in biomarkers (aminotransferases, caspases, cytokertins) and development of liver-related outcomes. Although emricasan was safe, there was no reduction in HVPG or biomarkers.111 Similarly, another randomized placebo-controlled trial with NASH patients with F1-F3 fibrosis with emricasan (5 mg or 50 mg) for 72 weeks did not improve liver histology in patients with NASH fibrosis and showed a trend towards worsening of fibrosis and ballooning.112 This drug is unlikely to hold promise.

**Selonsertib:** Selonsertib is an inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory and antifibrotic properties. A preliminary study of NASH was conducted with F2-3 fibrosis patients treated with selonsertib at 6 mg or 18 mg orally alone or in combination with simtuzumab (125 mg subcutaneously weekly) or simtuzumab alone for 24 weeks. The study demonstrated a decrease in hepatic collagen with the use of selonsertib.113 A follow-up study that used magnetic resonance imaging (MRI)-based evaluation of fibrosis assessment in patients receiving selonsertib showed a positive trend warranting further investigations.114 Two subsequent randomized, double-blind, placebo-controlled, phase 3 trials of selonsertib in patients with NASH and bridging fibrosis F3 (STELLAR-3) to 6 mg/kg and placebo-controlled trial with NASH patients with F1-F3 fibrosis with emricasan (5 mg or 50 mg) for 72 weeks did not improve liver histology in patients with NASH fibrosis and showed a trend towards worsening of fibrosis and ballooning.115 Neither of these trials met the primary endpoint, and no improvement in fibrosis was noted. The inhibitory effect of tipelukast on the 5-LO/LT pathway may contribute to its antibibiotic effects. In an interim report of nine NASH/NAFLD patients with hypertriglyceridemia who completed tipelukast (MN-001) at 250 mg qd for the first 4 weeks, tipelukast significantly reduced triglycerides.116 The complete results are awaited (NCT02681055).

**Volixibat:** Volixibat (SHP626) is a potent inhibitor of the apical sodium-dependent bile acid transporter (ASBT). In the initial phase 1 study, the absorption of the drug was found to be very low after oral ingestion.118 The drug was reviewed based on the hypothesis that ASBT inhibition in the terminal ileum would facilitate the removal of free cholesterol in the liver by reducing the recirculation of bile acids to the liver and promote other beneficial effects.119 A randomized controlled trial comparing volixibat at 0.5 mg, 1 mg, 5 mg, or 10 mg against placebo for 28 days in healthy volunteers and T2DM patients showed increased fecal excretion of bile acids with an increase of serum C4 levels in both groups.119 A recent randomized, double-blind trial
recruited steatosis and non-cirrhotic NASH patients treated with volibixat at 5 mg, 10 mg, or 20 mg or placebo once daily for 48 weeks. The study failed to reach the primary endpoint, which was defined as a ≥5% reduction in MRI proton density fat fraction (PDF) and ≥20% reduction in serum ALT level at interim analysis at 24 weeks, and the study was terminated.

**NS-0200:** The 5′ adenosine monophosphate-activated protein kinase (AMPK)/Sir21 pathway is a crucial regulator of mitochondrial biogenesis, energy, and lipid metabolism. Activation of this pathway may reverse or at least prevent excess hepatic lipid accumulation and inflammation. L-leucine is an activator of the SIRT1/AMPK or at least prevent excess hepatic lipid accumulation and protein kinase (AMPK)/Sirtuin 1 (Sirt1) pathway is a crucial regulatory node in nonalcoholic fatty liver disease (NAFLD). The study revealed that high-dose NS-0200 relatively reduced hepatic fat by 15.7% from baseline in the high ALT group (p<0.005), while no such benefit was seen at lower doses. The combination of leucine with low-dose metformin reversed hepatic steatosis in preclinical studies in murine models of T2DM and NASH. Adding low-dose sildenafil enhances this effect by stimulating endothelial nitric oxide synthase activity, leading to exacerbated stimulation of Sirt1 and thereby attenuating inflammation and fibrosis. The combination of leucine with low-dose metformin reversed hepatic steatosis in preclinical studies in murine models of T2DM and NASH. Adding low-dose sildenafil enhances this effect by stimulating endothelial nitric oxide synthase activity, leading to exacerbated stimulation of Sirt1 and thereby attenuating inflammation and fibrosis.

**Conflict of interest**

None to declare.

**Author contributions**

Conceptualization and study design (MS, AVK), data acquisition (MS, MP), initial drafting of the manuscript (MS, AVK, MP), figure generation (MS, PK), critical assessment of the manuscript, and provision of intellectual input (DNR, PNR), article guarantor (AVK). All authors approved the final draft.

**References**

[1] Issa D, Patel V, Sanyal AJ. Future therapy for non-alcoholic fatty liver disease. Liver Int 2018;38(9):1546–63. doi:10.1111/lINESS.13676.
[2] Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389–398. doi:10.1016/S2468-1253(19)30039-1.
[3] Manchanda R, Viggiano TH, McGill OB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434–438.
[4] Eslam M, Sanyal AJ, George J. NAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999–2014.e1. doi:10.1053/j.gastro.2019.11.312.
[5] Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008;14:6395–6400. doi:10.3748/wjg.14.6395.
[6] Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675–1685. doi:10.1056/NEJMoa0909729.
[7] Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. A randomized controlled trial of nonalcoholic steatohepatitis results of a randomized trial. Hepatology 2004;39:770–778. doi:10.1002/hep.20092.
[8] Levine JE, Schwimmer JB, Van Natta ML, Mollerson JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659–1666. doi:10.1001/jama.2011.9033.
[9] Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE, Weltman AL, et al. Prevalence, incidence, and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170. doi:10.1016/j.metabol.2020.154170.
[10] Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015;47:1999–2014.e1. doi:10.1053/j.gastro.2019.11.312.
[11] Johnston MP, Patel J, Byrne CD. Multi-drug approaches to NASH: what’s in the pipeline are OCA, which is awaiting FDA approval and metformin-sildenafil fixed-dose combination that attenuating inflammation and fibrosis. The effect by stimulating endothelial nitric oxide synthase activity, leading to exacerbated stimulation of Sirt1 and thereby attenuating inflammation and fibrosis.

**Conclusions**

Although many drugs fared well in animal models, the clinical utility of these drugs is limited in humans. The animal models are usually controlled for various confounders, and hence they may be an accurate representation of disease. However, no animal models can completely replicate the heterogeneous nature and physiological condition of human beings. The response to an injury is different in each individual. Hence, very few drugs have managed to progress into use in clinical practice. Despite many drugs being under evaluation, the only established treatment of NASH at this point is weight loss. Medications are currently used with no FDA approval as an adjunct to lifestyle changes in patients with biopsy-proven NASH. The two drugs approved in the pipeline are QCA, which is awaiting FDA approval and soraglitazar, which has been approved only in India for use in NASH, although long-term data on fibrosis improvement are still awaited.

**Funding**

None to declare.
Koppe SW, Tovili F, Napoli L, Serio J, Ferris S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885–904. doi:10.1007/s00125-011-2464-6.

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gravert B, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:485–904. doi:10.1007/s00125-011-2464-6.

Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials. J Hepatol 2020;72:135–140. doi:10.1016/j.jhep.2019.10.006.

Bourgon R, Kowdley KV, Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A, Kowdley KV, et al. Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100–110. doi:10.1053/j.gastro.2008.02.051.

Bourgon R, Kowdley KV, Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A, Kowdley KV, et al. Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100–110. doi:10.1053/j.gastro.2008.02.051.

Bourgon R, Kowdley KV, Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A, Kowdley KV, et al. Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100–110. doi:10.1053/j.gastro.2008.02.051.

Bourgon R, Kowdley KV, Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A, Kowdley KV, et al. Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100–110. doi:10.1053/j.gastro.2008.02.051.

Bourgon R, Kowdley KV, Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A, Kowdley KV, et al. Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100–110. doi:10.1053/j.gastro.2008.02.051.
Sharma M. et al: Pharmacotherapy for NASH

Journal of Clinical and Translational Hepatology 2021 vol. 9 | 40–50

49
Sharma M. et al: Pharmacotherapy for NASH

al. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterol 2018;18:3. doi:10.1186/s12876-017-0736-0.

[120] Newsome PN, Palmer M, Freilich B, Sheikh MY, Sheikh A, Sarles H, et al. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. J Hepatol 2020;73:231–240. doi:10.1016/j.jhep.2020.03.024.

[121] Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008;283:20015–20026. doi:10.1074/jbc.M802187200.

[122] Banerjee J, Bruckbauer A, Zemel MB. Activation of the AMPK/Sirt1 pathway by a leucine-metformin combination increases insulin sensitivity in skeletal muscle, and stimulates glucose and lipid metabolism and increases life span in Caenorhabditis elegans. Metabolism 2016;65:1679–1691. doi:10.1016/j.metabol.2016.06.011.

[123] Fu L, Bruckbauer A, Li F, Cao Q, Cui X, Wu R, et al. Interaction between metformin and leucine in reducing hyperlipidemia and hepatic lipid accumulation in diet-induced obese mice. Metabolism 2015;64:1426–1434. doi:10.1016/j.metabol.2015.07.006.

[124] Bruckbauer A, Banerjee J, Fu L, Li F, Cao Q, Cui X, et al. A combination of leucine, metformin, and sildenafil treats non-alcoholic fatty liver disease and steatohepatitis in mice. Int J Hepatol 2016;2016:9185987. doi:10.1155/2016/9185987.

[125] Chalasani N, Vuppallanchi R, Rinella M, Middleton MS, Siddiqui MS, Barritt AS4th, et al. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2018;47:1639–1651. doi:10.1111//apt.14674.